Search

Author/Creator Bolstad, N.

1. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial. (12th April 2019)

Authors:
Goll, G. L.; Jørgensen, K. K.; Sexton, J.; Olsen, I. C.; Bolstad, N.; Haavardsholm, E. A.; Lundin, K. E. A.; Tveit, K. S.; Lorentzen, M.; Berset, I. P.; Fevang, B. T. S.; Kalstad, S.; Ryggen, K.; Warren, D. J.; Klaasen, R. A.; Asak, Ø.; Baigh, S.; Blomgren, I. M.; Brenna, Ø.; Bruun, T. J.
Journal:
Journal of internal medicine
Issue:
Volume 285:Number 6(2019)
Page Start:
653
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS. (June 2017)

Authors:
Kolstad, A.; Madsbu, U.; Beasley, M.; Bayne, M.; Illidge, T.; O'Rourke, N.; Lagerlöf, I.; Hájek, R.; Jurczak, W.; Willenbacher, E.; Blakkisrud, J.; Muftuler Løndalen, A.; Rojkjaer, L.; Baylor Curtis, L.; Bloma, M.; Turner, S.; Bolstad, N.; Spetalen, S.; Erlanson, M.; Nygaard, S.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
269
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. THU0123 Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. (15th July 2016)

Authors:
Glintborg, B.; Kringelbach, T.; Høgdall, E.; Sørensen, I.J.; Jensen, D.V.; Loft, A.G.; Hendricks, O.; Jensen Hansen, I.M.; Bolstad, N.; Grøn, K.; Eng, G.; Enevold, C.; Nielsen, C.H.; Warren, D.; Goll, G.; Gehin, J.; Johansen, J.S.; Hetland, M.L.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75(2016)Supplement 2
Page Start:
224
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. FRI0536 SERUM GOLIMUMAB CONCENTRATIONS AND ANTI-DRUG ANTIBODIES ARE ASSOCIATED WITH TREATMENT RESPONSE AND DRUG SURVIVAL IN PATIENTS WITH INFLAMMATORY JOINT DISEASES: DATA FROM THE NOR-DMARD STUDY. (2nd June 2020)

Authors:
Gehin, J. E.; Warren, D. J.; Syversen, S. W.; Lie, E.; Sexton, J.; Loli, L.; Wierød, A.; Bjøro, T.; Kvien, T. K.; Bolstad, N.; Goll, G. L.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
868
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. FRI0579 RHEUMATOID FACTOR IS ASSOCIATED WITH FALSELY ELEVATED RESULTS IN COMMERCIAL IMMUNOASSAYS: DATA FROM AN EARLY ARTHRITIS COHORT. (2nd June 2020)

Authors:
Gehin, J. E.; Klaasen, R. A.; Norli, E. S.; Syversen, S. W.; Goll, G. L.; Warren, D. J.; Kvien, T. K.; Nustad, K. J.; Mjaavatten, M. D.; Bolstad, N.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
893
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. FRI0663 The fine specificity of anti-drug antibody responses to originator and biosimilar infliximab: analyses across five diseases from the 52-week randomized nor-switch study. (12th June 2018)

Authors:
Goll, G. L.; Bolstad, N.; Iria, I.; Klaasen, R. A.; Jorgensen, K. K.; Olsen, I. C.; Valido, A.; Saavedra, M. J.; Fonseca, J. E.; Lundin, K.; Warren, D. J.; Haavardsholm, E.; Jahnsen, J.; Kvien, T. K.; Goncalves, J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
852
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. SAT0185 Certolizumab pegol serum levels ≥20 mg/l are associated with improvement in das28 in rheumatoid arthritis patients. data from the nor-dmard study. (12th June 2018)

Authors:
Gehin, J. E.; Syversen, S. W.; Warren, D. J.; Goll, G. L.; Sexton, J.; Strand, E. K.; Kvien, T. K.; Bolstad, N.; Lie, E.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
953
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. FRI0645 Anti-drug antibodies to certolizumab pegol are associated with low drug levels and reduced clinical response at 3 months in patients with inflammatory joint diseases. data from the nor-dmard study. (12th June 2018)

Authors:
Gehin, J. E.; Goll, G. L.; Warren, D. J.; Syversen, S. W.; Sexton, J.; Strand, E. K.; Kvien, T. K.; Bolstad, N.; Lie, E.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
844
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. SAT0261 Certolizumab pegol serum levels ≥20 mg/l are associated with treatment response in patients with axial spondyloarthritis. data from the nor-dmard study. (12th June 2018)

Authors:
Gehin, J.E.; Syversen, S.W.; Warren, D.J.; Goll, G.L.; Sexton, J.; Strand, E.K.; Kvien, T.K.; Bolstad, N.; Lie, E.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
994
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. AB0442 Long-term safety and efficacy of biosimilar infliximab (CT-P13) after switching from originator infliximab: results from the 26-week open label extension of a norwegian randomised trial. (12th June 2018)

Authors:
Goll, G.L.; Jørgensen, K.K.; Sexton, J.; Olsen, I.C.; Bolstad, N.; Lorentzen, M.; Haavardsholm, E.A.; Mørk, C.; Jahnsen, J.; Kvien, T.K.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
1383
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗